# Respiratory Syncytial Virus (RSV) Vaccine Safety Monitoring

⚠️ Anyone can contribute, provide insight/suggestions or request additional data [**here**](https://github.com/ospv/RSV/discussions).  
All you need is to register (anonymously if you want) to github. 

**Table of content of previous analyses:**
- [29DEC23](#29DEC23)
- [24NOV23](#24NOV23)
- [27OCT23](#27OCT23)

<a id="29DEC23"></a>  
On data lock point of 29 Dec 2023, the following quantitative signals for Arexvy (GSK) and Abrysvo (Pfizer) were detected:  

| Arexvy | Abrysvo |
|--------|---------|
| [Product use issue](https://ospv.github.io/RSV/2023_12_29%20-%20Product%20use%20issue%20post%20RSV%20(AREXVY).html) | [Syringe issue](https://ospv.github.io/RSV/2023_12_29%20-%20Syringe%20issue%20post%20RSV%20(ABRYSVO).html) |
| [Exposure during pregnancy](https://ospv.github.io/RSV/2023_12_29%20-%20Exposure%20during%20pregnancy%20post%20RSV%20(AREXVY).html) | [Exposure during pregnancy](https://ospv.github.io/RSV/2023_12_29%20-%20Exposure%20during%20pregnancy%20post%20RSV%20(ABRYSVO).html) |
| [Product preparation issue](https://ospv.github.io/RSV/2023_12_29%20-%20Product%20preparation%20issue%20post%20RSV%20(AREXVY).html) | [Incorrect route of product administration]|
| [Product administered to patient of inappropriate age](https://ospv.github.io/RSV/2023_12_29%20-%20Product%20administered%20to%20patient%20of%20inappropriate%20age%20post%20RSV%20(AREXVY).html) | |
| [Injection site bruising](https://ospv.github.io/RSV/2023_12_29%20-%20Injection%20site%20bruising%20post%20RSV%20(AREXVY).html) | |
| [Wrong product administered](https://ospv.github.io/RSV/2023_12_29%20-%20Wrong%20product%20administered%20post%20RSV%20(AREXVY).html) | |
| [Atrial fibrillation](https://ospv.github.io/RSV/2023_11_24%20-%20Atrial%20fibrillation%20post%20RSV%20(AREXVY).html) | |
| [Needle issue](https://ospv.github.io/RSV/2023_12_29%20-%20Needle%20issue%20post%20RSV%20(AREXVY).html) | |
| [Peripheral swelling](https://ospv.github.io/RSV/2023_12_29%20-%20Peripheral%20swelling%20post%20RSV%20(AREXVY).html) | |
| [Injection site pruritus](https://ospv.github.io/RSV/2023_12_29%20-%20Injection%20site%20pruritus%20post%20RSV%20(AREXVY).html) | |

<a id="24NOV23"></a>  
On data lock point of 24 Nov 2023, the following quantitative signals for Arexvy (GSK) and Abrysvo (Pfizer) were detected:  

| Arexvy | Abrysvo |
|--------|---------|
| [Product use issue](https://ospv.github.io/RSV/2023_11_24%20-%20Product%20use%20issue%20post%20RSV%20(AREXVY).html) | [Syringe issue](https://ospv.github.io/RSV/2023_11_24%20-%20Syringe%20issue%20post%20RSV%20(ABRYSVO).html) |
| [Exposure during pregnancy](https://ospv.github.io/RSV/2023_11_24%20-%20Exposure%20during%20pregnancy%20post%20RSV%20(AREXVY).html) | [Exposure during pregnancy](https://ospv.github.io/RSV/2023_11_24%20-%20Exposure%20during%20pregnancy%20post%20RSV%20(ABRYSVO).html) |
| [Product preparation issue](https://ospv.github.io/RSV/2023_11_24%20-%20Product%20preparation%20issue%20post%20RSV%20(AREXVY).html) | [Incorrect route of product administration](https://ospv.github.io/RSV/2023_11_24%20-%20Incorrect%20route%20of%20product%20administration%20post%20RSV%20(AREXVY).html) |
| [Product administered to patient of inappropriate age](https://ospv.github.io/RSV/2023_11_24%20-%20Product%20administered%20to%20patient%20of%20inappropriate%20age%20post%20RSV%20(AREXVY).html) | |
| [Injection site bruising](https://ospv.github.io/RSV/2023_11_24%20-%20Injection%20site%20bruising%20post%20RSV%20(AREXVY).html) | |
| [Wrong product administered](https://ospv.github.io/RSV/2023_11_24%20-%20Wrong%20product%20administered%20post%20RSV%20(AREXVY).html) | |
| [Atrial fibrillation](https://ospv.github.io/RSV/2023_11_24%20-%20Atrial%20fibrillation%20post%20RSV%20(AREXVY).html) | |
| [Needle issue](https://ospv.github.io/RSV/2023_11_24%20-%20Needle%20issue%20post%20RSV%20(AREXVY).html) | |
| [Peripheral swelling](https://ospv.github.io/RSV/2023_11_24%20-%20Peripheral%20swelling%20post%20RSV%20(AREXVY).html) | |
| [Injection site pruritus](https://ospv.github.io/RSV/2023_11_24%20-%20Injection%20site%20pruritus%20post%20RSV%20(AREXVY).html) | |

<a id="27OCT23"></a>  
On data lock point of 27 Oct 2023, the [Safety Competitive Analysis Arexvy vs Abrysvo](https://ospv.github.io/RSV/2023_10_27%20-%20Safety%20Competitive%20Analysis%20-%20Arexvy%20vs%20Abrysvo.html) report highlighted the following quantitative signals for Arexvy (GSK) and Abrysvo (Pfizer):  

| Arexvy | Abrysvo |
|--------|---------|
| [Exposure during pregnancy](https://ospv.github.io/RSV/2023_10_27_SignalEval_Pregnancy_exposure.html) | [Incorrect route of product administration](https://ospv.github.io/RSV/2023_10_27%20-%20Incorrect%20route%20of%20product%20administration%20post%20Abrysvo.html) |
| [Product preparation issue](https://ospv.github.io/RSV/2023_10_27%20-%20Product%20preparation%20issue%20post%20Arexvy.html) | |
| [Product use issue](https://ospv.github.io/RSV/2023_10_27%20-%20Product%20use%20issue%20post%20Arexvy.html) | |
| [Peripheral swelling](https://ospv.github.io/RSV/2023_10_27%20-%20Peripheral%20swelling%20post%20Arexvy.html) |
| [Rash](https://ospv.github.io/RSV/2023_10_27%20-%20Rash%20post%20Arexvy.html) |
 
